Rebooting the microbiome

Using a murine Salmonella model of colitis, we recently reported that mice receiving a community of defined gut microbiota (MET-1) lost less weight, had reduced systemic inflammation and splenic S. typhimurium infection, and decreased neutrophil infiltration in the cecum, compared to vehicle control...

Full description

Saved in:
Bibliographic Details
Published in:Gut microbes 2016-07, Vol.7 (4), p.353-363
Main Authors: Munoz, Sean, Guzman-Rodriguez, Mabel, Sun, Jun, Zhang, Yong-guo, Noordhof, Curtis, He, Shu-Mei, Allen-Vercoe, Emma, Claud, Erika C., Petrof, Elaine O.
Format: Article
Language:English
Subjects:
Addenda
Animals
Clostridium difficile - physiology
Clostridium Infections - microbiology
Clostridium Infections - therapy
Colitis - microbiology
Colitis - therapy
DSS
epithelial barrier
Gastrointestinal Microbiome
Humans
Intestinal Mucosa - microbiology
Mice
Mice, Inbred C57BL
microbial ecosystem therapeutic
microbiota
salmonella
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Using a murine Salmonella model of colitis, we recently reported that mice receiving a community of defined gut microbiota (MET-1) lost less weight, had reduced systemic inflammation and splenic S. typhimurium infection, and decreased neutrophil infiltration in the cecum, compared to vehicle controls. In addition, animals receiving MET-1 exhibited preserved tight junction protein expression (Zonula occludens-1, claudin-1), suggesting important effects on barrier function. In this addendum, we describe additional in vitro experiments examining effects of MET-1, as well as in vivo experiments demonstrating that MET-1 is protective in a DSS model of colitis after administration of antibiotics. Placed in the context of our findings and those of others, we discuss differences in our findings between the Salmonella colitis and DSS colitis models, provide speculation as to which bacteria may be important in the protective effects of MET-1, and discuss potential implications for other GI diseases such as IBD.
ISSN:1949-0976
1949-0984
DOI:10.1080/19490976.2016.1188248